Skip to main content
SpringerLink
Log in

Kaposi Sarcoma

  • Chapter
  • First Online:
Uncommon Ulcers of the Extremities

Abstract

This chapter describes Kaposi sarcoma which has been a significant public health problem in sub-Saharan African nations. The epidemic variant of Kaposi sarcoma is regarded as an AIDS-defining illness. Kaposi sarcoma is causally linked to Human herpes virus-8 (HHV8) which is also called Kaposi sarcoma herpesvirus (KSHV) and presents with cutaneous and visceral manifestations. The chapter discusses the epidemiology of Kaposi sarcoma and its variants, clinical manifestations, staging, diagnosis (histology, immunohistochemistry and molecular testing), etiopathogenesis, and potential modes of transmission. In addition, it also describes the epidemiology and life cycle of HHV8/KSHV and how the virus strikes a delicate balance with the host’s immune system to create a long-lasting latent infection. Finally, the chapter describes the multi-modality management of Kaposi sarcoma for localised and disseminated disease, the prevention and early detection aspects of the disease and the quality of life of the patients with Kaposi sarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kaposi M. Idiopatisches multiples pigmentsarkom der haut [German]. Arch Dermatol Syph. 1872;4:265–73.

    Google Scholar 

  2. Chang Y, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science. 1994;266:1865–9.

    CAS  PubMed  Google Scholar 

  3. Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi sarcoma. Nat Rev Dis Primers. 2019;5(1):1–21.

    Google Scholar 

  4. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi’s Sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body cavity-based lymphomas. N Engl J Med. 1995;332:1186–91.

    CAS  PubMed  Google Scholar 

  5. Soulier J, et al. Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood. 1995;86:1275–80.

    Google Scholar 

  6. Gottlieb GJ, et al. A preliminary communication on extensively disseminated Kaposi’s sarcoma in young homosexual men. Am J Dermatopathol. 1981;3:111–4.

    CAS  PubMed  Google Scholar 

  7. Hymes KB, et al. Kaposi’s sarcoma in homosexual men—a report of eight cases. Lancet. 1981;2:598–600.

    CAS  PubMed  Google Scholar 

  8. Beral V, Peterman TA, Berkelman RL, Jaffe HW. Kaposi’s sarcoma among persons with AIDS: a sexually transmitted infection? Lancet. 1990;335:123–8.

    CAS  PubMed  Google Scholar 

  9. Elford J, McDonald A, Kaldor J. Kaposi’s sarcoma as a sexually transmissible infection: an analysis of Australian AIDS surveillance data. The National HIV Surveillance Committee. AIDS. 1993;7:1667–71.

    CAS  PubMed  Google Scholar 

  10. Hermans P, et al. Epidemiology of AIDS-related Kaposi’s sarcoma in Europe over 10 years. AIDS in Europe Study Group. AIDS. 1996;10:911–7.

    CAS  PubMed  Google Scholar 

  11. Wabinga HR, Parkin DM, Wabwire-Mangen F, Mugerwa JW. Cancer in Kampala, Uganda, in 1989-91: changes in incidence in the era of AIDS. Int J Cancer. 1993;54:26–36.

    CAS  PubMed  Google Scholar 

  12. Parkin DM, et al. Part I: cancer in indigenous Africans—burden, distribution, and trends. Lancet Oncol. 2008;9:683–92.

    PubMed  Google Scholar 

  13. Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: cancer today. Lyon: International Agency for Research on Cancer; 2020.

    Google Scholar 

  14. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi’s sarcoma in patients with and those without HIV infection. N Engl J Med. 1995;332(18):1181–5.

    CAS  PubMed  Google Scholar 

  15. Chuck S, Grant RM, Katongole-Mbidde E, Conant M, Ganem D. Frequent presence of a novel herpesvirus genome in lesions of human immunodeficiency virus-negative Kaposi's sarcoma. J Infect Dis. 1996;173(1):248–51.

    CAS  PubMed  Google Scholar 

  16. Buonaguro FM, Tornesello ML, Beth-Giraldo E, Hatzakis A, Mueller N, Downing R, Biryamwaho B, Sempala SD, Giraldo G. Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi’s sarcoma (KS) biopsies. Int J Cancer. 1996;65(1):25–8.

    CAS  PubMed  Google Scholar 

  17. Sitas F, Carrara H, Beral V, Newton R, Reeves G, Bull D, Jentsch U, Pacella-Norman R, Bourboulia D, Whitby D, Boshoff C. Antibodies against human herpesvirus 8 in black South African patients with cancer. N Engl J Med. 1999;340(24):1863–71.

    CAS  PubMed  Google Scholar 

  18. Purvis SF, Katongole-Mbidde E, Johnson JL, Leonard DG, Byabazaire N, Luckey C, Schick HE, Wallis R, Elmets CA, Giam CZ. High incidence of Kaposi’s sarcoma-associated herpesvirus and Epstein-Barr virus in tumor lesions and peripheral blood mononuclear cells from patients with Kaposi’s sarcoma in Uganda. J Infect Dis. 1997;175(4):947–50.

    CAS  PubMed  Google Scholar 

  19. Dupin N, Grandadam M, Calvez V, Aubin JT, Huraux JM, Agut H, Gorin I, Havard S, Lamy F, Leibowitch M, Escande JP. Herpesvirus-like DNA sequences in patients with Mediterranean Kaposi’s sarcoma. Lancet. 1995;345(8952):761–2.

    CAS  PubMed  Google Scholar 

  20. Gao SJ, Kingsley L, Hoover DR, Spira TJ, Rinaldo CR, Saah A, Phair J, Detels R, Parry P, Chang Y, Moore PS. Seroconversion to antibodies against Kaposi’s sarcoma–associated herpesvirus–related latent nuclear antigens before the development of Kaposi’s sarcoma. N Engl J Med. 1996;335(4):233–41.

    CAS  PubMed  Google Scholar 

  21. Roshan R, et al. T-cell responses to KSHV infection: a systematic approach. Oncotarget. 2017;8:109402–16.

    PubMed  PubMed Central  Google Scholar 

  22. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000;92:1823–30.

    Google Scholar 

  23. Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, Porter K. Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion. J Natl Cancer Inst. 2010;102:784–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Ibrahim Khalil A, Franceschi S, de Martel C, Bray F, Clifford GM. Burden of Kaposi sarcoma according to HIV status: a systematic review and global analysis. Int J Cancer. 2022;150(12):1948–57.

    CAS  PubMed  Google Scholar 

  25. Denis D, et al. A fifth subtype of Kaposi’s sarcoma, classic Kaposi’s sarcoma in men who have sex with men: a cohort study in Paris. J Eur Acad Dermatol Venereol. 2018;32:1377–84.

    CAS  PubMed  Google Scholar 

  26. What is Kaposi sarcoma? www.cancer.org, https://www.cancer.org/cancer/kaposi-sarcoma/about/what-is-kaposi-sarcoma.html. Accessed 29 May 2022.

  27. El-Mallawany NK, Villiera J, Kamiyango W, Peckham-Gregory EC, Scheurer ME, Allen CE, McAtee CL, Legarreta A, Dittmer DP, Kovarik CL, Chiao EY. Endemic Kaposi sarcoma in HIV-negative children and adolescents: an evaluation of overlapping and distinct clinical features in comparison with HIV-related disease. Infect Agents Cancer. 2018;13(1):1–7.

    Google Scholar 

  28. Fatahzadeh M. Kaposi sarcoma: review and medical management update. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113(1):2–16.

    PubMed  Google Scholar 

  29. Etta EM, Alayande DP, Mavhandu-Ramarumo LG, Gachara G, Bessong PO. HHV-8 seroprevalence and genotype distribution in Africa, 1998−2017: a systematic review. Viruses. 2018;10(9).

    Google Scholar 

  30. Bishop BN, Lynch DT. Kaposi sarcoma. In: StatPearls. StatPearls Publishing; 2021.

    Google Scholar 

  31. Radu O, Pantanowitz L. Kaposi sarcoma. Arch Pathol Lab Med. 2013;137(2):289–94.

    CAS  PubMed  Google Scholar 

  32. Bower M, DallaPria A, Coyle C, Andrews E, Tittle V, Dhoot S, Nelson M. Prospective stage-stratified approach to AIDS-related Kaposi’s sarcoma. J Clin Oncol. 2014;32(5):409–14.

    PubMed  Google Scholar 

  33. Zeichner SB, Ruiz AL, Suciu GP, Zeichner RL, Rodriguez E. Trends in Kaposi’s sarcoma in Miami Beach from 1987 to 2007. ISRN Oncol. 2012;2012.

    Google Scholar 

  34. Nichols CM, Flaitz CM, Hicks MJ. Treating Kaposi’s lesions in the HIV-infected patient. J Am Dent Assoc. 1993;124(11):78–84.

    CAS  PubMed  Google Scholar 

  35. Danzig JB, Brandt LJ, Reinus JF, Klein RS. Gastrointestinal malignancy in patients with AIDS. Am J Gastroenterol. 1991;86(6).

    Google Scholar 

  36. Laine L, Amerian J, Rarick M, Harb M, Gill PS. The response of symptomatic gastrointestinal Kaposi’s sarcoma to chemotherapy: a prospective evaluation using an endoscopic method of disease quantification. Am J Gastroenterol. 1990;85(8).

    Google Scholar 

  37. Joshi M, Markelova N, Palacio D, Schapira RM. A patient with HIV, dyspnea, and multiple pulmonary nodules. Chest. 2006;130(6):1924–8.

    PubMed  Google Scholar 

  38. Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1989;7:1201.

    CAS  PubMed  Google Scholar 

  39. Amerson E, et al. Accuracy of clinical suspicion and pathologic diagnosis of Kaposi sarcoma in East Africa. J Acquir Immune Defic Syndr. 2016;71:295–301.

    PubMed  PubMed Central  Google Scholar 

  40. Marušić Z, Billings SD. Histopathology of spindle cell vascular tumors. Surg Pathol Clin. 2017;10(2):345–66.

    PubMed  Google Scholar 

  41. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi’s sarcoma and a subset of angiosarcomas. Mod Pathol. 2002;15:434–40.

    PubMed  Google Scholar 

  42. Pyakurel P, et al. Lymphatic and vascular origin of Kaposi’s sarcoma spindle cells during tumor development. Int J Cancer. 2006;119:1262–7.

    CAS  PubMed  Google Scholar 

  43. Massarelli G, Scott CA, Ibba M, Tanda F, Cossu A. Immunocytochemical profile of Kaposi’s sarcoma cells: their reactivity to a panel of antibodies directed against different tissue cell markers. Appl Pathol. 1989;7:34–41.

    CAS  PubMed  Google Scholar 

  44. International Agency for Research on Cancer. In: IARC monographs on the evaluation of carcinogenic risks to humans, vol. 100B. International Agency for Research on Cancer; 2012.

    Google Scholar 

  45. Mesri EA, Cesarman E, Boshoff C. Kaposi’s sarcoma and its associated herpesvirus. Nat Rev Cancer. 2010;10(10):707–19.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Jha HC, Banerjee S, Robertson ES. The role of gammaherpesviruses in cancer pathogenesis. Pathogens. 2016;5(1):18.

    PubMed  PubMed Central  Google Scholar 

  47. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681–91.

    PubMed  Google Scholar 

  48. Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med. 1998;338(14):948–54.

    CAS  PubMed  Google Scholar 

  49. Butler LM, Osmond DH, Jones AG, Martin JN. Use of saliva as a lubricant in anal sexual practices among homosexual men. J Acquir Immune Defic Syndr. 2009;50:162–7.

    PubMed  PubMed Central  Google Scholar 

  50. Dukers NH, Rezza G. Human herpesvirus 8 epidemiology: what we do and do not know. AIDS. 2003;17(12):1717–30.

    PubMed  Google Scholar 

  51. Plancoulaine S, Abel L, van Beveren M, Trégouët DA, Joubert M, Tortevoye P, de Thé G, Gessain A. Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population. Lancet. 2000;356(9235):1062–5.

    CAS  PubMed  Google Scholar 

  52. Mantina H, Kankasa C, Klaskala W, Brayfield B, Campbell J, Du Q, Bhat G, Kasolo F, Mitchell C, Wood C. Vertical transmission of Kaposi’s sarcoma-associated herpesvirus. Int J Cancer. 2001;94(5):749–52.

    CAS  PubMed  Google Scholar 

  53. Hladik W, Dollard SC, Mermin J, Fowlkes AL, Downing R, Amin MM, Banage F, Nzaro E, Kataaha P, Dondero TJ, Pellett PE. Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med. 2006;355(13):1331–8.

    CAS  PubMed  Google Scholar 

  54. Barozzi P, Luppi M, Facchetti F, Mecucci C, AlĂ¹ M, Sarid R, Rasini V, Ravazzini L, Rossi E, Festa S, Crescenzi B. Post-transplant Kaposi sarcoma originates from the seeding of donor-derived progenitors. Nat Med. 2003;9(5):554–61.

    CAS  PubMed  Google Scholar 

  55. Luppi M, Barozzi P, Schulz TF, Setti G, Staskus K, Trovato R, Narni F, Donelli A, Maiorana A, Marasca R, Sandrini S. Bone marrow failure associated with human herpesvirus 8 infection after transplantation. N Engl J Med. 2000;343(19):1378–85.

    CAS  PubMed  Google Scholar 

  56. Bechtel JT, Liang Y, Hvidding J, Ganem D. Host range of Kaposi’s sarcoma-associated herpesvirus in cultured cells. J Virol. 2003;77:6474–81.

    CAS  PubMed  PubMed Central  Google Scholar 

  57. Kumar B, Roy A, Veettil MV, Chandran B. Insight into the roles of E3 ubiquitin ligase c-Cbl, ESCRT machinery, and host cell signaling in Kaposi’s sarcoma-associated herpesvirus entry and trafficking. J Virol. 2018;92:e01376–17.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Damania B, Cesarman E. In: Knipe DM, et al., editors. Field’s virology, vol. 2. Lippincott Williams & Wilkins; 2013. p. 2080–128.

    Google Scholar 

  59. Kumar B, Chandran B. KSHV entry and trafficking in target cells-hijacking of cell signal pathways, actin and membrane dynamics. Viruses. 2016;8:305.

    PubMed  PubMed Central  Google Scholar 

  60. Karabajakian A, Ray-Coquard I, Blay JY. Molecular mechanisms of Kaposi sarcoma development. Cancers. 2022;14(8):1869.

    CAS  PubMed  PubMed Central  Google Scholar 

  61. Zhu Q, Ding L, Zi Z, Gao S, Wang C, Wang Y, Zhu C, Yuan Z, Wei F, Cai Q. Viral-mediated AURKB cleavage promotes cell segregation and tumorigenesis. Cell Rep. 2019;26:3657–71.

    CAS  PubMed  Google Scholar 

  62. Kim YJ, Kim Y, Kumar A, Kim CW, Toth Z, Cho NH, Lee H-R. Kaposi’s sarcoma-associated herpesvirus latency associated nuclear antigen dysregulates expression of MCL-1 by targeting FBW7. PLoS Pathog. 2021;17:e1009179.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Tagawa T, Serquiña A, Kook I, Ziegelbauer J. Viral non-coding RNAs: stealth strategies in the tug-of-war between humans and herpesviruses. Semin Cell Dev Biol. 2021;111:135–47.

    CAS  PubMed  Google Scholar 

  64. Withers JB, Mondol V, Pawlica P, Rosa-Mercado NA, Tycowski KT, Ghasempur S, Torabi SF, Steitz JA. Idiosyncrasies of viral noncoding RNAs provide insights into host cell biology. Annu Rev Virol. 2019;6:297–317.

    CAS  PubMed  PubMed Central  Google Scholar 

  65. Suffert G, Malterer G, Hausser J, Viiliäinen J, Fender A, Contrant M, Ivacevic T, Benes V, Gros F, Voinnet O, et al. Kaposi’s sarcoma herpesvirus microRNAs target caspase 3 and regulate apoptosis. PLoS Pathog. 2011;7:e1002405.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Li T, Ju E, Gao SJ. Kaposi sarcoma-associated herpesvirus miRNAs suppress CASTOR1-mediated mTORC1 inhibition to promote tumorigenesis. J Clin Invest. 2019;129:3310–23.

    PubMed  PubMed Central  Google Scholar 

  67. Abend JR, Uldrick T, Ziegelbauer JM. Regulation of tumor necrosis factor-like weak inducer of apoptosis receptor protein (TWEAKR) expression by Kaposi’s sarcoma-associated herpesvirus microRNA prevents TWEAK-induced apoptosis and inflammatory cytokine expression. J Virol. 2010;84:12139–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  68. Tagawa T, Gao S, Koparde VN, Gonzalez M, Spouge JL, Serquiña AP, Lurain K, Ramaswami R, Uldrick TS, Yarchoan R, et al. Discovery of Kaposi’s sarcoma herpesvirus-encoded circular RNAs and a human antiviral circular RNA. Proc Natl Acad Sci U S A. 2018;115:12805–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Wakeham K, Johnston WT, Nalwoga A, Nalwoga A, Webb EL, Mayanja BN, Miley W, Elliott AM, Whitby D, Newton R. Trends in Kaposi’s sarcoma-associated Herpesvirus antibodies prior to the development of HIV-associated Kaposi’s sarcoma: a nested case-control study. Int J Cancer. 2015;136:2822–30.

    CAS  PubMed  Google Scholar 

  70. Yang TY, Chen SC, Leach MW, Manfra D, Homey B, Wiekowski M, Sullivan L, Jenh C-H, Narula SK, Chensue SW, et al. Transgenic expression of the chemokine receptor encoded by human herpesvirus 8 induces an angioproliferative disease resembling Kaposi’s sarcoma. J Exp Med. 2000;191:445–54.

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Zhang Z, Chen W, Sanders M, Brulois KF, Dittmer DP, Damania B. The K1 protein of Kaposi’s sarcoma associated herpesvirus augments viral lytic replication. J Virol. 2016;90:7657–66. Cancers 2022, 14, 1869 11 of 13.

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Gramolelli S, Weidner-Glunde M, Abere B, Viejo-Borbolla A, Bala K, RĂ¼ckert J, Kremmer E, Schulz TF. Inhibiting the recruitment of PLCγ1 to Kaposi’s sarcoma herpesvirus K15 protein reduces the invasiveness and angiogenesis of infected endothelial cells. PLoS Pathog. 2015;11:e1005105.

    PubMed  PubMed Central  Google Scholar 

  73. Gaglia MM. Kaposi’s sarcoma-associated herpesvirus at 27. Tumour Virus Res. 2021;12:200223. https://doi.org/10.1016/j.tvr.2021.200223.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Parsons CH, Szomju B, Kedes DH. Susceptibility of human fetal mesenchymal stem cells to Kaposi sarcoma-associated herpesvirus. Blood. 2004;104:2736–8.

    CAS  PubMed  Google Scholar 

  75. Adler B, Sattler C, Adler H. Herpesviruses and their host cells: a successful liaison. Trends Microbiol. 2017;25(3):229–41.

    CAS  PubMed  Google Scholar 

  76. Labo N, et al. Heterogeneity and breadth of host antibody response to KSHV infection demonstrated by systematic analysis of the KSHV proteome. PLoS Pathog. 2014;10:e1004046.

    PubMed  PubMed Central  Google Scholar 

  77. Olp LN, et al. Longitudinal analysis of the humoral response to Kaposi’s sarcoma-associated herpesvirus after primary infection in children. J Med Virol. 2016;88:1973–81.

    CAS  PubMed  Google Scholar 

  78. Coscoy L, Ganem D. Kaposi’s sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc Natl Acad Sci U S A. 2000;97:8051–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Ishido S, Wang C, Lee BS, Cohen GB, Jung JU. Downregulation of major histocompatibility complex class I molecules by Kaposi’s sarcoma-associated herpesvirus K3 and K5 proteins. J Virol. 2000;74:5300–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Jacobs SR, et al. The viral interferon regulatory factors of Kaposi’s sarcoma-associated herpesvirus differ in their inhibition of interferon activation mediated by toll-like receptor 3. J Virol. 2013;87:798–806.

    CAS  PubMed  PubMed Central  Google Scholar 

  81. Burysek L, et al. Functional analysis of human herpesvirus 8-encoded viral interferon regulatory factor 1 and its association with cellular interferon regulatory factors and p300. J Virol. 1999;73:7334–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  82. Ma Z, et al. Modulation of the cGAS-STING DNA sensing pathway by gammaherpesviruses. Proc Natl Acad Sci U S A. 2015;112:E4306–15.

    CAS  PubMed  PubMed Central  Google Scholar 

  83. Wu JJ, et al. Inhibition of cGAS DNA sensing by a herpesvirusvirion protein. Cell Host Microbe. 2015;18:333–44.

    CAS  PubMed  PubMed Central  Google Scholar 

  84. Zhang G, et al. Cytoplasmic isoforms of Kaposi sarcoma herpesvirus LANA recruit and antagonize the innate immune DNA sensor cGAS. Proc Natl Acad Sci U S A. 2016;113:E1034–43.

    CAS  PubMed  PubMed Central  Google Scholar 

  85. Nicholas J, et al. Kaposi’s sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat Med. 1997;3:287–92.

    CAS  PubMed  Google Scholar 

  86. Foster-Cuevas M, Wright GJ, Puklavec MJ, Brown MH, Barclay AN. Human herpesvirus 8 K14 protein mimics CD200 in down-regulating macrophage activation through CD200 receptor. J Virol. 2004;78:7667–76.

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Rezaee SA, Gracie JA, McInnes IB, Blackbourn DJ. Inhibition of neutrophil function by the Kaposi’s sarcoma-associated herpesvirus vOX2 protein. AIDS. 2005;19:1907–10.

    CAS  PubMed  Google Scholar 

  88. Chung YH, Means RE, Choi JK, Lee BS, Jung JU. Kaposi’s sarcoma-associated herpesvirus OX2 glycoprotein activates myeloid-lineage cells to induce inflammatory cytokine production. J Virol. 2002;76:4688–98.

    CAS  PubMed  PubMed Central  Google Scholar 

  89. Writing Group, Bower M, Palfreeman A, Alfa-Wali M, Bunker C, Burns F, Churchill D, Collins S, Cwynarski K, Edwards S, Fields P. British HIV Association guidelines for HIV-associated malignancies 2014. HIV Med. 2014;15:1–92.

    Google Scholar 

  90. Stewart S, et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol. 1998;16:683–91.

    CAS  PubMed  Google Scholar 

  91. Northfelt DW, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998;16:2445–51.

    CAS  PubMed  Google Scholar 

  92. Gill PS, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma. J Clin Oncol. 1996;14:2353–64.

    CAS  PubMed  Google Scholar 

  93. Esdaile B, et al. The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi’s sarcoma. AIDS. 2002;16:2344–7.

    CAS  PubMed  Google Scholar 

  94. Lichterfeld M, et al. Treatment of HIV-1-associated Kaposi’s sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery. Infection. 2005;33:140–7.

    CAS  PubMed  Google Scholar 

  95. Stebbing J, et al. Paclitaxel for anthracycline-resistant AIDS-related Kaposi’s sarcoma: clinical and angiogenic correlations. Ann Oncol. 2003;14:1660–6.

    CAS  PubMed  Google Scholar 

  96. Tulpule A, et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer. 2002;95:147–54.

    CAS  PubMed  Google Scholar 

  97. Cianfrocca M, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma. Cancer. 2010;116:3969–77.

    PubMed  Google Scholar 

  98. Nasti G, et al. AIDS-related Kaposi’s sarcoma: evaluation of potential new prognostic factors and assessment of the AIDS Clinical Trial Group staging system in the Haart Era—the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. J Clin Oncol. 2003;21:2876–82.

    PubMed  Google Scholar 

  99. El Amari EB, et al. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. AIDS. 2008;22:1019–28.

    PubMed  Google Scholar 

  100. Chu KM, et al. AIDS-associated Kaposi’s sarcoma is linked to advanced disease and high mortality in a primary care HIV programme in South Africa. J Int AIDS Soc. 2010;13:23.

    PubMed  PubMed Central  Google Scholar 

  101. Stebbing J, et al. The presentation and survival of patients with non-cutaneous AIDS-associated Kaposi’s sarcoma. Ann Oncol. 2006;17:503–6.

    CAS  PubMed  Google Scholar 

  102. World Health Organization. Consolidated guidelines on HIV prevention, diagnosis, treatment, and care for key populations: policy brief—2016 update. WHO; 2017.

    Google Scholar 

  103. U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. AIDSinfo; 2018. https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines.

  104. National Cancer Institute, National Institutes of Health. About cancer: infectious agents. National Cancer Institute; 2017. https://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents.

Download references

Author information

Authors and Affiliations

  1. Department of Preventive Oncology, Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Tata Memorial Centre, Varanasi, India

    Divya Khanna

  2. Department of Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India

    Ajay K. Khanna

Authors
  1. Divya Khanna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ajay K. Khanna
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute of Medical Sciences, Department of Surgery, Banaras Hindu University, Varanasi, India

    Ajay K. Khanna

  2. Institute of Medical Sciences, Department of General Surgery, Banaras Hindu University, Varanasi, India

    Satyendra Kumar Tiwary

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Khanna, D., Khanna, A.K. (2023). Kaposi Sarcoma. In: Khanna, A.K., Tiwary, S.K. (eds) Uncommon Ulcers of the Extremities. Springer, Singapore. https://doi.org/10.1007/978-981-99-1782-2_26

Download citation

  • DOI: https://doi.org/10.1007/978-981-99-1782-2_26

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-99-1781-5

  • Online ISBN: 978-981-99-1782-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation